Current role
Diana Hausman, M.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Diana Hausman, M.D.
Zentalis Pharmaceuticals, Inc. reported in an 8-K filed January 25, 2024 that Diana Hausman, M.D. resigned as member of the Board of Directors, effective January 19, 2024. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed January 25, 2024 that Diana Hausman, M.D. was appointed Chief Medical Officer, effective January 19, 2024.
“Dr. Hausman resigned from the Board, the Audit Committee of the Board ("Audit Committee"), and the Nominating and Corporate Governance Committee of the Board.”
“Diana Hausman, M.D., a member of the Company’s Board of Directors (the "Board"), had succeeded Carrie Brownstein, M.D. as Chief Medical Officer of the Company, effective January 19, 2024 (the "Transition Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-01-19–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Zentalis Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Julie Eastland CEO, Board Member
- Kimberly Blackwell, M.D. CEO
- David M. Johnson Chairman
- Scott Myers Chairman, Board Member
- Cam Gallagher CFO
- Vincent Vultaggio CFO, Chief Accounting Officer
- Iris Roth COO
- Iris Roth, Ph.D. COO
- James B. Bucher General Counsel
- David Johnson Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.